Bart L. Scott
About
Bart L. Scott is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, Bart L. Scott has authored 169 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 152 papers in Hematology, 66 papers in Genetics and 40 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Bart L. Scott's work include Acute Myeloid Leukemia Research (133 papers), Hematopoietic Stem Cell Transplantation (61 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (51 papers). Bart L. Scott is often cited by papers focused on Acute Myeloid Leukemia Research (133 papers), Hematopoietic Stem Cell Transplantation (61 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (51 papers). Bart L. Scott collaborates with scholars based in United States, Germany and Italy. Bart L. Scott's co-authors include H. Joachim Deeg, Frederick R. Appelbaum, Barry E. Storer, Rainer Storb, Brenda M. Sandmaier, Mohamed L. Sorror, Michael B. Maris, Ted Gooley, David G. Maloney and Richard T. Maziarz and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Bart L. Scott
164 papers receiving 4.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bart L. Scott United States | 35 | 3.8k | 1.6k | 1.0k | 1.0k | 509 | 169 | 4.3k | ||
| Sherry Pierce United States | 36 | 3.5k 0.9× | 1.3k 0.8× | 1.8k 1.7× | 971 0.9× | 897 1.8× | 131 | 4.5k | ||
| Claude Gardin France | 35 | 3.2k 0.9× | 1.1k 0.7× | 1.9k 1.9× | 800 0.8× | 750 1.5× | 123 | 4.3k | ||
| Åsa Rangert Derolf Sweden | 19 | 2.2k 0.6× | 1.2k 0.7× | 1.2k 1.2× | 613 0.6× | 525 1.0× | 42 | 2.8k | ||
| H. Kantarjian United States | 29 | 2.4k 0.6× | 2.1k 1.3× | 995 1.0× | 781 0.8× | 637 1.3× | 120 | 3.9k | ||
| Maria Concetta Petti Italy | 32 | 2.9k 0.8× | 811 0.5× | 2.0k 1.9× | 698 0.7× | 625 1.2× | 112 | 3.7k | ||
| Renato Bassan Italy | 32 | 2.4k 0.6× | 983 0.6× | 664 0.6× | 2.1k 2.1× | 1.2k 2.3× | 164 | 4.2k | ||
| Michael J. Barnett Canada | 30 | 1.8k 0.5× | 1.0k 0.6× | 474 0.5× | 516 0.5× | 698 1.4× | 115 | 2.9k | ||
| Carlos Graux Belgium | 27 | 2.2k 0.6× | 581 0.4× | 1.1k 1.1× | 1.4k 1.3× | 980 1.9× | 91 | 3.6k | ||
| Mar Tormo Spain | 32 | 2.1k 0.5× | 506 0.3× | 1.3k 1.3× | 1.0k 1.0× | 646 1.3× | 106 | 3.1k | ||
| Thomas J. Nevill Canada | 25 | 1.8k 0.5× | 632 0.4× | 471 0.5× | 449 0.4× | 761 1.5× | 99 | 2.5k |
Countries citing papers authored by Bart L. Scott
Since
Specialization
Citations
This map shows the geographic impact of Bart L. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart L. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart L. Scott more than expected).
Fields of papers citing papers by Bart L. Scott
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Bart L. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart L. Scott. The network helps show where Bart L. Scott may publish in the future.
Co-authorship network of co-authors of Bart L. Scott
This figure shows the co-authorship network connecting the top 25 collaborators of Bart L. Scott. A scholar is included among the top collaborators of Bart L. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart L. Scott. Bart L. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Orvain, Corentin, Megan Othus, Eduardo Rodríguez‐Arbolí, et al.. (2024). Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS /AML or AML . American Journal of Hematology. 99(5). 862–870.
2.
Saber, Wael, Aasthaa Bansal, Bart L. Scott, et al.. (2024). Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102. JCO Oncology Practice. 20(4). 572–580.
3.
Gagelmann, Nico, Rachel B. Salit, Thomas Schroeder, et al.. (2024). Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation. Bone Marrow Transplantation. 59(8). 1154–1160.
4.
Oh, Stephen T., Ruben A. Mesa, Claire Harrison, et al.. (2023). Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Advances. 7(19). 5835–5842.
5.
Gagelmann, Nico, Anita Badbaran, Rachel B. Salit, et al.. (2023). Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 141(23). 2901–2911.
6.
Muffly, Lori, Catherine J. Lee, Ankur Varma, et al.. (2022). Preliminary Data from a Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning Is Well-Tolerated, Facilitates Chimerism and Clearance of Minimal Residual Disease in Older Adults with MDS/AML Undergoing Allogeneic HCT. Transplantation and Cellular Therapy. 28(3). S476–S478.
7.
Jacoby, Meagan A., David A. Sallman, Bart L. Scott, et al.. (2021). A Pilot Study of CPX-351 (Vyxeos ©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome. Blood. 138(Supplement 1). 540–540.
8.
Maziarz, Richard T., Mark J. Levis, Mrinal M. Patnaik, et al.. (2020). Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplantation. 56(5). 1180–1189.
9.
Zhang, Ling, Donald M. Stablein, Pearlie K. Epling‐Burnette, et al.. (2018). Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study. Blood. 132(Supplement 1). 4370–4370.
10.
Gerds, Aaron T., Bart L. Scott, Peter L. Greenberg, et al.. (2018). PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. Blood. 132(Supplement 1). 466–466.
11.
Rashidi, Armin, Ryan Shanley, Sophia Yohe, et al.. (2018). Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft‐versus‐host disease: analysis of BMT CTN‐0201 and ‐0901 samples. British Journal of Haematology. 182(6). 887–894.
12.
Ma, Xiaomei, David P. Steensma, Bart L. Scott, et al.. (2018). Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. BMJ Open. 8(7). e019955–e019955.
13.
Maziarz, Richard T., Mrinal M. Patnaik, Bart L. Scott, et al.. (2018). Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML. Blood. 132(Supplement 1). 662–662.
14.
Lima, Marcos de, Betül Oran, Richard E. Champlin, et al.. (2017). Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). Blood. 130. 4512–4512.
15.
Yeung, Cecilia C.S., Aaron T. Gerds, Min Fang, et al.. (2015). Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing. Biology of Blood and Marrow Transplantation. 21(9). 1565–1575.
16.
Laille, Eric, Michael R. Savona, Bart L. Scott, et al.. (2013). Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. The Journal of Clinical Pharmacology. 54(6). 630–639.
17.
Vaughn, Jennifer, Bart L. Scott, & H. Joachim Deeg. (2013). Transplantation for myelodysplastic syndromes 2013. Current Opinion in Hematology. 20(6). 494–500.
18.
Scott, Bart L.. (2012). Discussion. The American Journal of Medicine. 125(7). S33–S34.
19.
Eissa, Hesham, Ted Gooley, Mohamed L. Sorror, et al.. (2010). Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities. Biology of Blood and Marrow Transplantation. 17(6). 908–915.
20.
Kerbauy, Daniella, Ted Gooley, Mohamed L. Sorror, et al.. (2005). Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation. 11(9). 713–720.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sherry Pierce Breakdown of academic impact, for papers by Claude Gardin Breakdown of academic impact, for papers by Åsa Rangert Derolf Breakdown of academic impact, for papers by H. Kantarjian Breakdown of academic impact, for papers by Maria Concetta Petti Breakdown of academic impact, for papers by Renato Bassan Breakdown of academic impact, for papers by Michael J. Barnett Breakdown of academic impact, for papers by Carlos Graux Breakdown of academic impact, for papers by Mar Tormo Breakdown of academic impact, for papers by Thomas J. Nevill